Insuman Comb 30 Solostar

Insulin Human, the active ingredient in Insuman Comb 30 Solostar, is an insulin presented as a subcutaneous solution for subcutaneous use. It is used to control blood glucose in patients with diabetes mellitus, both type 1 and type 2.

GNH USA supplies Insuman Comb 30 Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant shipments to global markets.

Insuman Comb 30 Solostar is an insulin preparation indicated for the management of diabetes mellitus, targeting both basal and prandial glucose control.

- Type 1 diabetes mellitus: provides basal and mealtime insulin to achieve glycemic control. - Type 2 diabetes mellitus: used when oral agents are insufficient, offering combined basal‑bolus coverage. - Insulin‑deficient states: supplies patients requiring exogenous insulin to replace deficient endogenous secretion.

Insuman Comb 30 Solostar may be associated with several adverse reactions, ranging from frequent to rare.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight due to improved glucose utilization. - Lipodystrophy: localized fat tissue changes at injection sites. - Edema: mild peripheral swelling. - Nausea: occasional gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological symptoms or loss of consciousness. - Anaphylactic reaction: life‑threatening allergy requiring immediate medical attention. - Insulin allergy: systemic rash, urticaria, or angioedema. - Serum sickness–like reaction: fever, arthralgia, and rash. - Hypokalemia: low potassium levels, especially with high doses. - Seizures: secondary to profound hypoglycemia.

When using Insuman Comb 30 Solostar, several precautions should be observed to ensure safe and effective therapy.

- Dose adjustment: tailor insulin dose to individual blood‑glucose monitoring results. - Renal impairment: monitor closely as reduced clearance may increase hypoglycemia risk. - Hepatic impairment: use with caution; altered metabolism may affect glucose control. - Pregnancy: limited safety data; evaluate risk‑benefit before prescribing. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 30 Solostar can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent sulfonylureas: additive hypoglycemia risk. - Beta‑blockers: may mask hypoglycemia symptoms. - Alcohol: can potentiate insulin’s glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may increase blood glucose, requiring dose adjustment. - Corticosteroids: can raise glucose levels, potentially necessitating higher insulin doses. - ACE inhibitors: may affect potassium balance, warranting monitoring.